Overall, we observed that MUC4/MUC16/MUC20 signature harbored an increased hazard ratio compared with MUC4 alone for pancreatic cancer and to a lower extent in bladder cancer, colon cancer, lung squamous cancer and stomach cancer. This evidence concerns the gene MUC16 and familial pancreatic carcinoma.